E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Biotechnology Applications of Marine Biosurfactants"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 31 December 2019

Special Issue Editor

Guest Editor
Prof. Lígia R. Rodrigues

CEB—Centre of Biological Engineering, University of Minho, 4710-057 Braga, Portugal
Website | E-Mail
Phone: +351253604400
Interests: Biosurfactants; Bioactive Molecules; Adhesion and Biofilms; Synthetic biology; Industrial Biotechnology; Bioprocess development; Functional food and biomarkers

Special Issue Information

Dear Colleagues,

Marine-derived biosurfactants have not been widely explored and despite their promising biotechnological applications, industrial uses are limited. Besides the difficulties associated with the isolation and culture of their producers, the main factors include their low yields, scarce structural elucidation and unknown biosynthetic pathways. The marine environment is extremely diverse and encloses a huge source of organisms potentially able to produce new biosurfactants with unique activities spanning from antimicrobial, anti-adhesive, anti-biofilm to anti-cancer, among others. This issue will include recent advances in the discovery of novel marine-derived biosurfactants with significant biological activities; the use of omics to explore the marine environment biodiversity and unravel the biosynthetic pathways involved in biosurfactants production; the physicochemical and functional characterization of marine-derived biosurfactants and their potential applications; the production and process scale-up of marine-biosurfactants; and the cost-efficiency of the production process, circular (bio)economy and industrial demands.

Prof. Lígia R. Rodrigues
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Marine-derived biosurfactants
  • (Bio)prospection, Screening, Isolation, Culture
  • Metagenomics (sequence-based, function-based)
  • Structural characterization, Biosynthetic pathways
  • Antimicrobial activity, Anti-adhesive activity, Anti-biofilm activity, Anti-cancer activity, Anti-inflammatory activity, Antioxidant activity
  • Therapeutics, Nutraceuticals, Functional food, Cosmetics
  • Production, Recovery and Scale-up
  • Process Sustainability and Circular (Bio)economy

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle
Characterization of Antifungal Lipopeptide Biosurfactants Produced by Marine Bacterium Bacillus sp. CS30
Mar. Drugs 2019, 17(4), 199; https://doi.org/10.3390/md17040199
Received: 18 March 2019 / Revised: 26 March 2019 / Accepted: 27 March 2019 / Published: 29 March 2019
PDF Full-text (3970 KB) | HTML Full-text | XML Full-text
Abstract
This study was initiated to screen for marine bacterial agents to biocontrol Magnaporthe grisea, a serious fungal pathogen of cereal crops. A bacterial strain, isolated from the cold seep in deep sea, exhibited strong growth inhibition against M. grisea, and the [...] Read more.
This study was initiated to screen for marine bacterial agents to biocontrol Magnaporthe grisea, a serious fungal pathogen of cereal crops. A bacterial strain, isolated from the cold seep in deep sea, exhibited strong growth inhibition against M. grisea, and the strain was identified and designated as Bacillus sp. CS30. The corresponding antifungal agents were purified by acidic precipitation, sequential methanol extraction, Sephadex LH-20 chromatography, and reversed phase high-performance liquid chromatography (RP-HPLC), and two antifungal peaks were obtained at the final purification step. After analysis by mass spectrometry (MS) and tandem MS, two purified antifungal agents were deduced to belong to the surfactin family, and designated as surfactin CS30-1 and surfactin CS30-2. Further investigation showed that although the antifungal activity of surfactin CS30-1 is higher than that of surfactin CS30-2, both of them induced the increased generation of reactive oxygen species (ROS) and caused serious damage to the cell wall and cytoplasm, thus leading to the cell death of M. grisea. Our results also show the differences of the antifungal activity and antifungal mechanism of the different surfactin homologs surfactin CS30-1 and surfactin CS30-2, and highlight them as potential promising agents to biocontrol plant diseases caused by M. grisea. Full article
(This article belongs to the Special Issue Biotechnology Applications of Marine Biosurfactants)
Figures

Figure 1

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top